Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Lupin is the 6th largest company in the Indian Pharmaceutical Market
he US FDA has issued six observations pursuant to the completion of the audit.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Subscribe To Our Newsletter & Stay Updated
